Skip to content

Jagwire M00556650Recalls & reported problems

Boston Scientific Corporation · High Performance Guidewire · Class 2

Data updated Oct 13, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 08714729747345), received between May 30, 2023 and May 30, 2023 — classified as 1 injury.

The most frequently reported specific device problem is “Break” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.

Most reported problems

Device problems

  • Break1
  • Use of Device Problem1

Patient problems

  • Pancreatitis1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryMay 30, 2023Break; Use of Device Problem; Break; Use of Device Problem

    IT WAS REPORTED TO BOSTON SCIENTIFIC CORPORATION THAT A JAGWIRE WAS USED IN THE BILE DUCT DURING AN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) PROCEDURE PERFORMED ON AN UNKNOWN DATE. DURING THE PROCEDURE, PART OF THE JAGWIRE DETACHED INTO THE PANCREATIC DUCT CAUSING PANCREATITIS IN THE PATIENT. IT WAS REPORTED THAT THE PATIENT BOUGHT THE GUIDEWIRE IN TO THE SITE. IT WAS NOTED THAT THE GUIDEWIRE EXPIRED BASED ON THE LOT AND BATCH NUMBER (M00556651 AND 18495289) PROVIDED BACK IN 07OCT2018. ADDITIONALLY, ACCORDING TO THE DISTRIBUTOR THIS GUIDEWIRE HAD NOT BEEN SOLD BY THEM. NO FURTHER INFORMATION HAS BEEN OBTAINED DESPITE GOOD FAITH EFFORTS.

    Patient problems: Pancreatitis

    MAUDE report 17026151 ↗

Other Endoscopic guidewire, gastroenterology-urology devices

All Endoscopic guidewire, gastroenterology-urology devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page